English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Recent studies have resulted in a variety of therapeutic options for cancer. However, tumor patients, even a same patient at different disease stages, respond(s) to a treatment protocol with different efficacy. A concept of personalized medicine has been developed to deliver individually tailored treatment upon the unique responsiveness of each patient. Currently, it is still challenging to predict treatment outcomes due to the genetic complexity and heterogeneity of cancers, which underlies the varied responses to treatment. To efficiently design treatment strategies and monitor the outcomes of therapies for individual patient, tumor responsiveness to a specific treatment regimen needs to be assesses in a timeand cost-efficient manner. Non-invasive imaging technologies have demonstrated great potentials in diagnosis and treatment management by monitoring individual patient’s disease condition and progression. Currently, anatomic and functional imaging modalities have been generally applied to detect, stage, and monitor tumors. Compared to the anatomic imaging that measures tumor size, functional or molecular imaging provides more information on tumor metabolism, biomarker expression, cell death or proliferation and thus is more relevant to the imaging assessment of tumor responsiveness to a treatment regimen, especially when the treatment affects tumors through blocking the tumor progression instead of shrinking the tumor size. Discovery of novel probes that specifically binds to tumor-limited targets with sound biological relevance is a limiting factor to develop such functional imaging modality. Compared to antibody (~150 kD), peptide is in a much smaller size (1-2 kD) that enables an improved tissue penetration, faster clearance from circulation system, and less immunogenic property that are expected for a imaging probe, especially in the repeated assessment of treatment responsiveness in solid tumors. Advances in phage display-related technologies have facilitated the discovery and development of peptide derivatives as imaging probes for a variety of tumors. By using one example of HVGGSSV peptide that has

Phage-Displayed Recombinant Peptides for Non-Invasive Imaging Assessment of Tumor Responsiveness to Ionizing Radiation and Tyrosine Kinase Inhibitors